We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
An FDA inspection of the Zhejiang Huahai Pharmaceutical plant a year ahead of its global recall of tainted heart drug valsartan found a plant with little regard for quality control and which blamed out-of-specification test results on “ghost peaks,” lab e